Quality of Care Measures
Colon and Rectal Cancers
The following three colon and rectal cancer quality-focused measures have been endorsed by the National Quality Forum (NQF). With submission of EMHC-specific data to the National Cancer Data Base (NCDB) we are able to compare our compliance rate of these accountability or quality improvement measures against state and national rates. These measures not only emphasize the quality of patient care but also the importance of accurate and complete documentation.
Comparison data below is for colon and rectal cancer cases diagnosed in calendar year 2007.
| EMHC | IL | ALL | |
|---|---|---|---|
Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer. [ACT] |
100% |
89.6% |
82.4% |
At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer. [12RLN] |
100% |
78% |
74.7% |
Radiation therapy is considered or administered within 6 months (180 days) of diagnosis for patients under the age of 80 with clinical or pathologic AJCC T4N0M0 or Stage III receiving surgical resection for rectal cancer. [Rec/RT] |
100% |
93.4% |
84.7% |
EMHC: Elmhurst Memorial Healthcare |
|||
Breast Cancer
The following three breast cancer quality-focused measures have been endorsed by the National Quality Forum (NQF). With submission of EMHC-specific data to the National Cancer Data Base (NCDB) we are able to compare our compliance rate of these accountability measures against state and national rates. These measures not only emphasize the quality of patient care but also the importance of accurate and complete documentation.
Comparison data below is for breast cancer cases diagnosed in calendar year 2007.
| EMHC | IL | ALL | |
|---|---|---|---|
Radiation therapy is administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conserving surgery for breast cancer. [BCS/RT] |
97.5% |
87% |
78.9% |
Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under age 70 with AJCC T1cN0M0, or Stage II or III hormone receptor negative breast cancer. [MAC] |
87.5% |
85.5% |
80.5% |
Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or Stage II or III hormone receptor positive breast cancer. [HT] |
94.1% |
71.5% |
62.7% |
EMHC: Elmhurst Memorial Healthcare |
|||
Subscribe to the EMHC E-Mail Newsletter
- Receive periodic e-mail updates from EMHC on health topics, new campus information and more.
- Subscribe Today
Latest New Campus News
- See the latest information concerning EMHC’s new integrated campus in south Elmhurst.
- View All New Campus Press Releases
Health Connections
- Elmhurst Memorial Healthcare's community magazine on upcoming events, services and technological advancements.
- View Health Connections